NEW DELHI – In a test of India's law requiring sponsors of patented drugs to manufacture sufficient quantities in country, Cipla Ltd.'s challenge of Novartis AG's Indian patent for its chronic obstructive pulmonary disorder (COPD) drug Onbrez is raising questions about access, price and the correct way to contest a pharmaceutical patent.